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PD1-1:
REST MODULATES HYPOXIA-INDUCED NEUROENDOCRINE
DIFFERENTIATION OF PROSTATE CANCER CELLS BY ACTIVATING
AUTOPHAGY SIGNALING
Tzu-Ping Lin 1,2, Yi-Ting Chang 3, Sung-Yuan Lee 3, Pei-Ching
Chang 3. 1Department of Urology, Taipei Veterans General Hospital, Taipei,
Taiwan; 2Department of Urology, School of Medicine, and Shu-Tien
Urological Research Center, National Yang-Ming University, Taipei, Taiwan;
3 Institute of Microbiology and Immunology, National Yang-Ming University,
Taipei, Taiwan
Purpose: To study the role of element-1 silencing transcription factor(R-
EST) in hypoxia induced neuroendocrine differentiation(NED) of prostate
cancer.
Materials and Methods: Prostate cancer cell line LNCaP was cultured in
hypoxic chamber to induce NED. Neuroendocrine differentiation was quan-
tiﬁed by neurite length measurement by phase-contrast optical microscope.
Inducible REST knock down and overexpression LNCaP cell line was estab-
lished and used to determine the effect of REST in NED in LNCaP cells. RNA
was harvested from hypoxia-treated LNCaP, normoxia LNCaP, induced REST
knock down LNCaP cells and sequenced with Illumina Genome AnalyzerII.
Results: REST, a transcriptional repressor of neuronal genes that has been
implicated in androgen-deprivation and IL-6 induced NED, is essential for
hypoxia-induced NED of PCa cells. Bioinformatics analysis of transcriptome
proﬁle of REST knockdown with hypoxia treatment demonstrated that
REST is a master regulator of hypoxia-induced genes. Gene set enrichment
analysis (GSEA) of hypoxia and REST knockdown co-upregulated genes
revealed their correlation with HRPC. Consistently, gene ontology (GO)
analysis showed that REST reduction potential associated with hypoxia-
induced tumorigenesis, NE development, and AMPK pathway activation.
Conclusion: REST knockdown alone is capable of activating AMPK and
autophagy activation is essential for hypoxia-induced NED of PCa cells.
PD1-2:
INHIBITION OF CISPLATIN-INDUCED AUTOPHAGY ENHANCES
APOPTOTIC CELL DEATH IN HUMAN BLADDER CANCER CELLS
Thomas I-Sheng Hwang 1,2,3,4, Ji-Fan Lin 5, Yi-Chia Lin 1, Te-Fu Tsai 1, Hung-
En Chen 1, Kuang-Yu Chou 1. lDepartment of Surgery, Shin Kong Wu Ho-Su
Memorial Hospital, Taipei, Taiwan; 2Department of Urology, Shin Kong Wu
Ho-Su Memorial Hospital, Taipei, Taiwan; 3Department of Urology, Taipei
Medical University, Taipei, Taiwan; 4Division of Urology, School of
Medicine, Fu-Jen Catholic University, Taipei, Taiwan; 5Central Laboratory,
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
Purpose: Bladder cancer (BC) is a common urologic cancer with high
recurrence rate. Cisplatin is the ﬁrst member of a class of platinum-con-
taining anti-cancer drugs that binding to and causing DNA cross-linking
which ultimately leads to apoptosis. Cisplatin is used to treat various types of
cancers including BC. However, cisplatin alone is not very effective in BC and1879-5226/ Copyright © 2015, Taiwan Urological Association. Published by Elsevier Ta
creativecommons.org/licenses/by-nc-nd/4.0/).the combinations of gemcitabine/cisplatin is now the ﬁrst-line chemo-
therapy for muscle invasive BC. Our previous studies showed that BC cells
exhibits high basal level of autophagy and treatment of chemotherapeutic
agents further induces autophagy as a survival mechanism. In this study, we
investigated if cisplatin induces autophagy in human BC cells and whether
inhibition of cisplatin-induced autophagy enhances cancer cell death.
Materials and Methods: The cell viability of RT4 (grade I), 5637 (grade II),
and T24 (grade III) humanbladder cancer cells treatedwith cisplatin alone or
combinedwith autophagy inhibitor, baﬁlomycinA1 (BafA1),was accessedby
WST-8 cell viability kit. The autophagy status in cells was performed by the
detection of microtubule-associated light chain 3 form II (LC3-II) using
immunoﬂuorescent staining and Western blot. Moreover, the formation of
autophagolysosomewasdetectedusing transmission electronmicroscopy to
conﬁrm the induction of autophagy in cisplatin-treated T24 cells. To inves-
tigate the signaling pathway involved in cisplatin-induced autophagy, the
activation of AKT, ERK, AMPK and MAPK and the inhibition of mTOR in
cisplatin-treated cells were detected using Western blot. Induced apoptosis
was determined by the detection of cleavage caspase 3, and the measure-
ment of caspase 3/7 activity and DNA fragmentation in treated-cells.
Results: Advanced bladder cancer cells (5637 and T24) were more resis-
tant to cisplatin than RT4. The processing of LC3-II was elevated in cells
treated with increased concentration of cisplatin, suggesting cisplatin in-
duces autophagy. Detection of autophagy ﬂux by blocking autophgosome
to lysosomes fusion using Baf A1 and the direct observation of autopha-
golysosome formation in cisplatin-treated T24 cells using TEM further
conﬁrmed that cisplatin indeed triggers autophagy in BC cells. Activation
of AKT, ERK and MAPK signaling and inhibition of mTOR was detected in
cisplatin treated cells. However, pretreatment of speciﬁc inhibitors of ERK,
MAPK did not attenuated cisplatin-induced autophagy suggests these
pathways are not involved in the induction of autophagy. Finally, reduced
cell viability and induced apoptosis were observed in cisplatin-treated
cells pretreated with autophagy inhibitor suggesting that inhibition of
autophagy enhances cancer killing effect of cisplatin in human BC cells.
Conclusion: Cisplatin induces autophagy through activation of AKT and
inhibition of mTOR in human BC cells. Our data suggest that autophagy
inhibition promotes apoptosis in cisplatin-treated cells, and could be a
new therapeutic paradigm for the treatment of bladder cancer.
PD1-3:
NOVEL BLADDER CANCER BIOMARKERS DISCOVERY BY
MICRODISSECTED COMPARATIVE TISSUE PROTEOMICS
Chien-Lun Chen, Ting Chung, Chih-Ching Wu, Kwai-Fong Ng, Jau-Song
Yu, Cheng-Han Tsai, Yu-Sun Chang, Ying Liang, Ke-Hung Tsui, Yi-Ting
Chen. Department of Urology, Chang Gung Memorial Hospital, Linko Chang
Gung University, Taoyuan, Taiwan
Purpose: More than 380,000 new cases of bladder cancer are diagnosed
worldwide, accounting for 150,200 deaths each year. No reliable biomarker
for bladder cancer is used clinically. We employed a strategy combining
laser microdissection, isobaric tags for relative and absolute quantitation
labeling, and liquid chromatography-tandem MS (LC-MS/MS) analysis to
proﬁle proteomic changes in fresh-frozen bladder tumor specimens.iwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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resected primary bladder cancer tumor and adjacent nontumorous tissue
were extracted for two batches of isobaric tags for relative and absolute
quantitation (iTRAQ) experiments. The DAVID (database for annotation,
visualization and integrated discovery) is used for analysis of dysregulated
proteins. ELISA were employed for validation of candidate tumor markers
in tissues and the age-matched urine specimens from bladder cancer pa-
tients and hernia patients as control were compared.
Results: The iTRAQ experiments identiﬁed a total of 3220 proteins. Seven
differentially expressed proteins were selected as potential bladder cancer
biomarkers for further veriﬁcation. Immunohistochemical analyses
showed signiﬁcantly elevated levels of three proteins- SLC3A2, STMN1, and
TAGLN2- in tumor cells compared with noncancerous bladder epithelial
cells, and suggested that TAGLN2 could be a useful tumor tissue marker for
diagnosis (AUC¼ 0.999). The DAVID analysis revealed three top-ranking
biological processes as involved in extracellular matrix organization,
extracellular structure organization, and oxidation-reduction. ELISA
revealed signiﬁcantly increased urinary levels of both STMN1 and TAGLN2
in bladder cancer subgroups compared with control groups. Urinary
TAGLN2 in bladder cancer samples showed the largest fold change (7.13-
fold), with an AUC value of 0.70 (p < 0.001, n¼ 205).
Conclusion: Our study discovered that TAGLN2 showed the most signiﬁ-
cant over expression in bladder cancer tissues and urine specimens, and
thus represents a potential biomarker for noninvasive screening for
bladder cancer.
PD1-4:
ANALYSIS OF PROSTATE CANCER FOCI IN PATIENTS WITH TRANSRECTAL
10-CORE SYSTEMIC RANDOM BIOPSYdCAN WE PREDICT
PATHOLOGICAL STAGE OF PROSTATE CANCER THROUGH TRUS BIOPSY?
Kuan-Yu Wu, Yuh-Shyan Tsai, Wen-Horng Yang, Tzong-Shin
Tzai. Department of Urology, College of Medicine and Hospital, National
Cheng Kung University, Tainan, Taiwan
Purpose: The aim of this study is evaluating the detection site of prostate
cancer foci in patients receiving transrectal ultrasound(TRUS) guided 10-
core systemic random biopsy and comparing the relationship between
digital rectal examination and prostatic biopsy. The study ultimately aims
to predict pathological staging of prostate cancer by TRUS-biopsy.
Materials and Methods: Between September 2005 and June 2014, 1314
men received TRUS-guided biopsy were included in this study. Indications
for TRUS guided prostate biopsy were: abnormal digital rectal examination
and/or a serum PSA over 4.0 ng/ml. 701 patients were excluded due to less
than 10 cores or received target biopsy and 68 patients were excluded due
to different machine. Finally, 545 patients underwent at least 10-core
random biopsy protocol by TRUS and 46 of those patients treated with
radical retropubic prostatectomy.
Results: Of the 545 patients, one hundred and ﬁfty-two (27.9%) were
positive for prostate cancer, including 64 of 370 (16.2 %) men with normal
DRE and 88 of 175 (50.3 %) with abnormal DRE. Patients with normal DRE
exhibited younger age (67.9 vs. 71.0 yrs, p¼ 0.007), lower serum PSA(15.7
vs. 25.6 ng/ml, p¼ 0.0032), lower PSA density(0.41 vs. 0.71, p¼ 0.0016),
less positive cores(p¼ 0.022), and less Gleason score(p¼ 0.0006) than
those with abnormal DRE.
46 of those patients treated with radical retropubic prostatectomy,
including 17 men with normal DRE and 29 with abnormal DRE. The
pathological ﬁnding revealed higher number of positive biopsy cores in
advanced staging whether digital ﬁnding was positive or not. For eval-
uating the association of the detection site of prostate cancer foci and
pathological staging, we deﬁned low, intermittent, and high risk group
according to number of positive cores in different locations (lateral,
parasagittal, and apical area). We identiﬁed low risk group with no
positive core. Intermittent risk group means one positive core or 2
positive cores ipsilateral (2S). High risk group means 2 positive cores
contralateral (2C) or number of positive cores more than 3. Otherwise,
we also reclassiﬁed pathological staging into 3 subgroups: pT2a and
pT2b, pT2c, and pT3a at least. The pathological ﬁnding of patient with
low risk group will below pT2c and high-risk group will above pT3.
(p¼ 0.031 in lateral sites, p¼ 0.007 in parasagittal sites, and p¼ 0.023 in
apical sites).Conclusions: In our study, patient with normal digital rectal examination
and PSA elevation received TURS-biopsy has 16% malignancy change. Be-
sides, patients with abnormal digital rectal examination received TURS-
biopsy has 50% malignancy change. Patients with normal DRE exhibited
younger age, lower serum PSA, lower PSA density, less positive cores, and
less Gleason score than those with abnormal DRE. The cancer foci detected
by biopsies of the prostate are equally distributed even subgroup analysis
depending on location of positive cores or prostate size. Prediction of
pathological stage in prostate cancer through TRUS 10-core random biopsy
is available in this study.
PD1-5:
DOWNREGULATION OF MIR-145 PREDICTS A WORSE OUTCOME IN
UPPER TRACT UROTHELIAL CARCINOMAS
Hung-Lung Ke 1,2,4, Hui-Hui Lin 2,4, Wei-Ming Li 1,2,4,6, Chun-Nung
Huang 1,2,4, Ching-Chia Li 1,2,4,5, Lin-Li Chang 1,3, Hsin-Chih
Yeh 1,2,4,5, Wen-Jeng Wu 1,2,4,5. 1Graduate Institute of Medicine, College of
Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 2Department
of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung,
Taiwan; 3Department of Microbiology, College of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan; 4Department of Urology, Kaohsiung
Medical University Hospital, Kaohsiung Municipal Ta-Tung Hospital,
Kaohsiung Medical University, Kaohsiung, Taiwan; 5Department of Urology,
Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University,
Kaohsiung, Taiwan; 6 Pingtung Hospital, Department of Health, Executive
Yuan, Pingtung, Taiwan
Purpose:MicroRNAs (miRNAs) represent a class of small non-coding RNAs
regulating gene expression by inducing the degradation of RNA or inter-
fering with translation. Aberrant miRNA expression has been described in
several types of cancer in humans. By our pre-set miR array data, we iden-
tiﬁed miR-145 as the most signiﬁcant tumor suppressor mir in urothelial
carcinoma (UC). However, the expression of miR-145 in UC of the upper
urinary tract (UTUC) has not been investigated. This study is conducted to
evaluate the outcome predictive value of miR-145 expression in UTUC.
Materials and Methods: Using a miRNA array (Applied Biosystems) that
included 667 human miRNAs and mammalian RNU6B, we compare the
differentially expressed miRNAs between BFTC909 cell line and paired
UTUC samples. The miR-145 expression levels from 65 UTUC tissues and
the paired adjacent noncancerous tissues were investigated by Real-Time
Reverse Transcriptase PCR assay. In addition, the functional consequences
of miR145 transfection in BFTC909 cells were studied in vitro by MTT,
wound healing, cell migration, cell invasion assays.
Results: In 65 paired tissues, we found that mir-145 expression was
signiﬁcantly decreased in UTUC tissues than in paired adjacent noncan-
cerous tissues. Decreased mir-145 expression was associated with worse
recurrence-free and cancer-speciﬁc survival. In cell line experiments, we
demonstrated that mir145 can inhibit cell proliferation, migration and
invasion in BFTC909 cell line after transfection of miR145 mimics.
Conclusion: Our ﬁndings imply that decreased miR-145 expression is a
potential biomarker to predict clinical outcome of UTUC patients. Further
study is necessary to identify the molecular mechanisms of miR-145
involved in the cancerous processes of UTUC.
PD1-6:
BY INHIBITING SNAIL SIGNALING, OSTHOLE SUPPRESSES THE EMT-
MEDIATED METASTATIC ABILITY IN PROSTATE CANCER
Yu-Ching Wen 1,3, Liang-Ming Lee 1, Ming-Hsien Chien 2,3. 1Department of
Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan;
2Department of Education and Research, Wan Fang Hospital, Taipei
Medical University, Taipei, Taiwan; 3Graduate Institute of Clinical Medicine,
Collage of Medicine, Taipei Medical University, Taipei, Taiwan
Purpose: To evaluate the anti-metastatic potential of osthole in prostate
cancer cells and xenograft animal model.
Materials andMethods: The PC3 and DU145 human adrogen independent
prostate cancer (AIPC) cell lines were obtained from American Type Cul-
ture Collection for cell assay. PC-3M, a highly metastatic subline derived
from the hepatic metastasis of PC-3 in nude mice, was used for xenograft
